880135 | DSPE-PEG(2000) Carboxylic Acid
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (sodium salt)
DSPE-PEG(2000) Carboxylic Acid
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (sodium salt)
The chemical name for DSPE PEG 2000 Carboxylic Acid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (sodium salt) or DSPE-PEG-COOH. Based on the polydispersity of PEG, its molecular weight is 2780.38, and its exact mass is 2778.7.
This specialized lipid molecule has been used in various applications in the field of biotechnology, pharmaceuticals, and drug delivery. It is a derivative of phospholipids and is part of the broader family of liposomal formulations.
The DSPE's hydrophobic characteristics facilitate the encapsulation and gathering of other hydrophobic drugs. In the presence of an activator like EDC or HATU, the -COOH group can readily react with primary amines, resulting in the formation of a stable amide bond.
DSPE-PEG 2000 carboxylic acid has been utilized to attach ITGA2 antibodies to liposome surfaces, create atosiban-conjugated liposomes, and produce dual complementary liposomes.
Avanti Research provides this 99% pure functionalized PEG lipid in powder form in 10 mg, 25 mg, 50 mg, 100 mg, and 500 mg packaging.
C 56.59%, H 9.32%, N 0.50%, Na 0.83%, O 31.65%, P 1.11%
CAS Registry Number is a Registered Trademark of the American Chemical Society
770135
Mashreghi M, Zamani P, Moosavian SA, Jaafari MR. Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma. Nanoscale Res Lett. 2020 May 7;15(1):101. doi: 10.1186/s11671-020-03334-9. PMID: 32383027; PMCID: PMC7206479.
PubMed ID: 32383027Kong L, Li XT, Ni YN, Xiao HH, Yao YJ, Wang YY, Ju RJ, Li HY, Liu JJ, Fu M, Wu YT, Yang JX, Cheng L. Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer's Disease-Related Pathology in APP/PS-1 Mice. Int J Nanomedicine. 2020 Apr 23;15:2841-2858. doi: 10.2147/IJN.S239608. PMID: 32425521; PMCID: PMC7186891.
PubMed ID: 32425521An J, Forchheimer D, Sävmarker J, Brülls M, Frenning G. Nanoscale characterization of PEGylated phospholipid coatings formed by spray drying on silica microparticles. J Colloid Interface Sci. 2020 May 21;577:92-100. doi: 10.1016/j.jcis.2020.05.045. Epub ahead of print. PMID: 32473480.
PubMed ID: 32473480Kuo YC, Lou YI, Rajesh R. Dual functional liposomes carrying antioxidants against tau hyperphosphorylation and apoptosis of neurons. J Drug Target. 2020 May 12:1-12. doi: 10.1080/1061186X.2020.1761819. Epub ahead of print. PMID: 32338078.
PubMed ID: 32338078Benne N, Martins Cardoso R, Boyle AL, Kros A, Jiskoot W, Kuiper J, Bouwstra J, Van Eck M, Slütter B. Complement Receptor Targeted Liposomes Encapsulating the Liver X Receptor Agonist GW3965 Accumulate in and Stabilize Atherosclerotic Plaques. Adv Healthc Mater. 2020 May;9(10):e2000043. doi: 10.1002/adhm.202000043. Epub 2020 Apr 24. PMID: 32329226.
PubMed ID: 32329226Wei Y, Liu S, Pan C, Yang Z, Liu Y, Yong J, Quan L. Molecular Antenna-Sensitized Upconversion Nanoparticle for Temperature Monitored Precision Photothermal Therapy. Int J Nanomedicine. 2020 Mar 2;15:1409-1420. doi: 10.2147/IJN.S236371. PMID: 32184595; PMCID: PMC7060035.
PubMed ID: 32184595Lee SWL, Campisi M, Osaki T, Possenti L, Mattu C, Adriani G, Kamm RD, Chiono V. Modeling Nanocarrier Transport across a 3D In Vitro Human Blood-Brain-Barrier Microvasculature. Adv Healthc Mater. 2020 Apr;9(7):e1901486. doi: 10.1002/adhm.201901486. Epub 2020 Mar 3. PMID: 32125776.
PubMed ID: 32125776Ye S , Liu Y , Lu Y , Ji Y , Mei L , Yang M , Gong X , Gu Q , Li D , Yang F , Li CJ . Cyclic RGD functionalized liposomes targeted to activated platelets for thrombosis dual-mode magnetic resonance imaging. J Mater Chem B. 2020 Jan 22;8(3):447-453. doi: 10.1039/c9tb01834d. PMID: 31833530.
PubMed ID: 31833530Ramesh A , Kumar S , Nguyen A , Brouillard A , Kulkarni A . Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy. Nanoscale. 2020 Jan 23;12(3):1875-1885. doi: 10.1039/c9nr08670f. PMID: 31903467.
PubMed ID: 31903467Yang F, Medik Y, Li L, Tian X, Fu D, Brouwer KLR, Wagner K, Sun B, Sendi H, Mi Y, Wang AZ. Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo. Small. 2020 Jan 23:e1906360. doi: 10.1002/smll.201906360. Epub ahead of print. PMID: 31972070.
PubMed ID: 31972070Kim K, Jo EJ, Lee KJ, Park J, Jung GY, Shin YB, Lee LP, Kim MG. Gold nanocap-supported upconversion nanoparticles for fabrication of a solid-phase aptasensor to detect ochratoxin A. Biosens Bioelectron. 2019 Nov 14:111885. doi: 10.1016/j.bios.2019.111885. [Epub ahead of print]
PubMed ID: 31759762Jie Zhang, Qi G, Xu C, Jin Y. Enzymatic Preparation of Plasmonic-Fluorescent Quantum Dot-Gold Hybrid Nanoprobes for Sensitive Detection of Glucose and Alkaline Phosphatase and Dual-Modality Cell Imaging. Anal Chem. 2019 Nov 5;91(21):14074-14079. doi: 10.1021/acs.analchem.9b03818. Epub 2019 Oct 18.
PubMed ID: 31592647Guo P, Huang J, Moses-Gardner A, Smith ER, Moses MA. Quantitative Analysis of Different Cell Entry Routes of Actively Targeted Nanomedicines Using Imaging Flow Cytometry. Cytometry A. 2019 Aug;95(8):843-853. doi: 10.1002/cyto.a.23848. Epub 2019 Jul 11.
PubMed ID: 31294926Meng L, Chu X, Xing H, Liu X, Xin X, Chen L, Jin M, Guan Y, Huang W, Gao Z. Improving glioblastoma therapeutic outcomes via doxorubicin-loaded nanomicelles modified with borneol. Int J Pharm. 2019 Aug 15;567:118485. doi: 10.1016/j.ijpharm.2019.118485. Epub 2019 Jun 29.
PubMed ID: 31260781Yung-Chih Kuo, Rajendiran Rajesh, Jyh-Ping Hsu. Electrophoretic mobility of neuron-like cells regenerated from iPSCs with induction of retinoic acid- and nerve growth factor-loaded solid lipid nanoparticles. Journal of the Taiwan Institute of Chemical Engineers. 2019 October;103:167-176. doi: 10.1016/j.jtice.2019.07.010
Wang Y, Fu M, Liu J, Yang Y, Yu Y, Li J, Pan W, Fan L, Li G, Li X, Wang X. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer. Int J Nanomedicine. 2019 May 31;14:4071-4090. doi: 10.2147/IJN.S194304. eCollection 2019.
PubMed ID: 31239668Qin Zeng, Yunxia Wu, and Tao Zhang. Photoacoustic nanoprobe for β-galactosidase activity detection and imaging in vivo. Journal of Innovative Optical Health Sciences. 27 February 2019. Vol. 12, No. 03, 1941001. doi: 10.1142/S1793545819410013
Lusi V, Moore TL, Laurino F, Coclite A, Perreira R, Ferreira M, Rizzuti I, Palomba R, Zunino P, Duocastella M, Mizrahy S, Peer D, Decuzzi P. A tissue chamber chip for assessing nanoparticle mobility in the extravascular space. Biomed Microdevices. 2019 Apr 6;21(2):41. doi: 10.1007/s10544-019-0398-5.
PubMed ID: 30955101Guo P, Moses-Gardner A, Huang J, Smith ER, Moses MA. ITGA2 as a potential nanotherapeutic target for glioblastoma. Sci Rep. 2019 Apr 17;9(1):6195. doi: 10.1038/s41598-019-42643-7.
PubMed ID: 30996239Hua S, Vaughan B. In vitro comparison of liposomal drug delivery systems targeting the oxytocin receptor: a potential novel treatment for obstetric complications. Int J Nanomedicine. 2019 Mar 27;14:2191-2206. doi: 10.2147/IJN.S198116. eCollection 2019.
PubMed ID: 30988616Guo P, Yang J, Liu D, Huang L, Fell G, Huang J, Moses MA, Auguste DT. Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis. Sci Adv. 2019 Mar 20;5(3):eaav5010. doi: 10.1126/sciadv.aav5010. eCollection 2019 Mar.
PubMed ID: 30906868Getachew Tedla, Jesse Plotkin, Anthony Dellinger, and Christopher Kepley. Design and Testing of Dual-Targeted Gd3N@C80-Containing Glioblastoma Theranostics. Journal of Nanomaterials, Vol. 2019, Article ID 1242930, 13 pages, 2019. https://doi.org/10.1155/2019/1....
Kim B, Pena CD, Auguste DT. Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1-/FOXM1+ Triple Negative Breast Cancer Cells. Mol Pharm. 2019 Mar 29. doi: 10.1021/acs.molpharmaceut.8b01065. [Epub ahead of print]
PubMed ID: 30883132Shim G, Kim D, Lee S, Chang RS, Byun J, Oh YK. Staphylococcus aureus-mimetic control of antibody orientation on nanoparticles. Nanomedicine. 2019 Feb;16:267-277. doi: 10.1016/j.nano.2018.09.007. Epub 2018 Oct 24.
PubMed ID: 30368001Rao J, Mei L, Liu J, Tang X, Yin S, Xia C, Wei J, Wan D, Wang X, Wang Y, Li M, Zhang Z, He Q. Size-adjustable micelles co-loaded with a chemotherapeutic agent and an autophagy inhibitor for enhancing cancer treatment via increased tumor retention. Acta Biomater. 2019 Apr 15;89:300-312. doi: 10.1016/j.actbio.2019.03.022. Epub 2019 Mar 14.
PubMed ID: 30878446Fan CH, Wang TW, Hsieh YK, Wang CF, Gao Z, Kim A, Nagasaki Y, Yeh CK. Enhancing Boron Uptake in Brain Glioma by a Boron-Polymer/Microbubble Complex with Focused Ultrasound. ACS Appl Mater Interfaces. 2019 Mar 27;11(12):11144-11156. doi: 10.1021/acsami.8b22468. Epub 2019 Mar 18.
PubMed ID: 30883079Kuo YC, Chang YH, Rajesh R. Targeted delivery of etoposide, carmustine and doxorubicin to human glioblastoma cells using methoxy poly(ethylene glycol)‑poly(ε‑caprolactone) nanoparticles conjugated with wheat germ agglutinin and folic acid. Mater Sci Eng C Mater Biol Appl. 2019 Mar;96:114-128. doi: 10.1016/j.msec.2018.10.094. Epub 2018 Nov 4.
PubMed ID: 30606517Zhang X, Kang Y, Liu GT, Li DD, Zhang JY, Gu ZP, Wu J. Poly(cystine-PCL) based pH/redox dual-responsive nanocarriers for enhanced tumor therapy. Biomater Sci. 2019 Feb 27. doi: 10.1039/c9bm00009g. [Epub ahead of print]
PubMed ID: 30810135Jen-Tsung Yang, Yung-Chih Kuo, I-Yin Chen, Rajendiran Rajesh, Yung-I Lou, and Jyh-Ping Hsu. Protection against Neurodegeneration in the Hippocampus Using Sialic Acid- and 5-HT-Moduline-Conjugated Lipopolymer Nanoparticles. ACS Biomater. Sci. Eng., Article ASAP
Fan CH, Lin YT, Ho YJ, Yeh CK. Spatial-Temporal Cellular Bioeffects from Acoustic Droplet Vaporization. Theranostics. 2018 Nov 10;8(20):5731-5743. doi: 10.7150/thno.28782. eCollection 2018.
PubMed ID: 30555577- Certificate of Analysis (Lot No. 880135P-100MG-A-010 and 6296PLA010)
- Certificate of Analysis (Lot No. 880135P-10MG-A-010 and 6296PIA010)
- Certificate of Analysis (Lot No. 880135P-25MG-A-010 and 6296PJA010)
- Certificate of Analysis (Lot No. 880135P-500MG-A-010 and 6296PPA010)
- Certificate of Analysis (Lot No. 880135P-50MG-A-010 and 6296PKA010)
- Certificate of Analysis (Lot No. 880135P-50MG-B-010 and 6296PKB010)
- Certificate of Analysis (Lot No. 880135P-500MG-A-011 and 6296PPA011)
- Certificate of Analysis (Lot No. 880135P-25MG-A-011 and 6296PJA011)
- Certificate of Analysis (Lot No. 880135P-10MG-A-011 and 6296PIA011)
- Certificate of Analysis (Lot No. 880135P-50MG-A-011 and 6296PKA011)
- Certificate of Analysis (Lot No. 880135P-100MG-A-011 and 6296PLA011)
- Certificate of Analysis (Lot No. 880135P-50MG-B-011 and 6296PKB011)
- Certificate of Analysis (Lot No. 880135P-100MG-B-011 and 6296PLB011)
- Certificate of Analysis (Lot No. 880135P-100MG-B-010 and 6296PLB010)
- Certificate of Analysis (Lot No. 880135P-25MG-B-010 and 6296PJB010)
- Certificate of Analysis (Lot No. 880135P-50MG-A-012 and 6296PKA012)
- Certificate of Analysis (Lot No. 880135P-10MG-A-012 and 6296PIA012)
- Certificate of Analysis (Lot No. 880135P-500MG-A-012 and 6296PPA012)
- Certificate of Analysis (Lot No. 880135P-50MG-B-012 and 6296PKB012)
- Certificate of Analysis (Lot No. 880135P-100MG-A-012 and 6296PLA012)
- Certificate of Analysis (Lot No. 880135P-25MG-A-012 and 6296PJA012)
- Certificate of Analysis (Lot No. 880135P-500MG-B-012 and 6296PPB012)
- Certificate of Analysis (Lot No. 880135P-100MG-B-012 and 6296PLB012)
- Certificate of Analysis (Lot No. 880135P-25MG-B-012 and 6296PJB012)
- Certificate of Analysis (Lot No. 880135P-50MG-C-012 and 6296PKC012)
- Certificate of Analysis (Lot No. 880135P-500MG-A-013 and 6296PPA013)
- Certificate of Analysis (Lot No. 880135P-500MG-B-013 and 6296PPB013)
- Certificate of Analysis (Lot No. 880135P-100MG-A-013 and 6296PLA01)
- Certificate of Analysis (Lot No. 880135P-500MG-A-014 and 6296PPA014)
- Certificate of Analysis (Lot No. 880135P-10MG-A-014 and 6296PIA014)
- Certificate of Analysis (Lot No. 880135P-500MG-B-014 and 6296PPB014)
- Certificate of Analysis (Lot No. 880135P-25MG-A-014 and 6296PJA014)
- Certificate of Analysis (Lot No. 880135P-50MG-C-015 and 6296PKC015)
- Certificate of Analysis (Lot No. 880135P-50MG-B-015 and 6296PKB015)
- Certificate of Analysis (Lot No. 880135P-10MG-B-015 and 6296PIB015)
- Certificate of Analysis (Lot No. 880135P-25MG-B-015 and 6296PJB015)
- Certificate of Analysis (Lot No. 880135P-500MG-C-015 and 6296PPC015)
- Certificate of Analysis (Lot No. 880135P-100MG-C-015 and 6296PLC015)
- Certificate of Analysis (Lot No. 880135P-100MG-D-015 and 6296PLD015)
- Certificate of Analysis (Lot No. 880135P-25MG-C-015 and 6296PJC015)
- Certificate of Analysis (Lot No. 880135P-10MG-D-015 and 6296PID015)
- Certificate of Analysis (Lot No. 880135P-25MG-D-015 and 6296PJD015)
- Certificate of Analysis (Lot No. 880135P-50MG-D-015 and 6296PKD015)
- Certificate of Analysis (Lot No. 880135P-500MG-A-016 and 6296PPA016)
- Certificate of Analysis (Lot No. 880135P-10MG-C-015 and 6296PIC015)
- Certificate of Analysis (Lot No. 880135P-10MG-E-015 and 6296PIE015)
- Certificate of Analysis (Lot No. 880135P-25MG-E-015 and 6296PJE015)
- Certificate of Analysis (Lot No. 880135P-25MG-F-015 and 6296PJF015)
- Certificate of Analysis (Lot No. 880135P-25MG-A-016 and 6296PJA016)
- Certificate of Analysis (Lot No. 880135P-100MG-B-016 and 6296PLB016)
- Certificate of Analysis (Lot No. 880135P-10MG-A-016 and 6296PIA016)
- Certificate of Analysis (Lot No. 880135P-50MG-B-016 and 6296PKB016)
- Certificate of Analysis (Lot No. 880135P-500MG-B-016 and 6296PPB016)